Each 1-percentage-point increase in HbA1c level was associated with a 14% increase in heart disease risk.

High-dose vitamin B may do more harm than good for heart disease, and homocysteine, billed as a heart disease risk factor, isn’t one after all, researchers reported.

The American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) have issued guidelines for the diagnosis and management of the metabolic syndrome.

The interim results, after 8 weeks of treatment, showed no change in fasting glucose while in post-prandial glucose there was a 15.4% reduction.

New data, suggest that the novel long-acting insulin, insulin detemir (Novo Nordisk) can be used in people with type 2 diabetes without causing weight gain of the degree that typically accompanies this progression of therapy.

Supplementation of a meal based on white wheat bread with vinegar reduced postprandial responses of blood glucose and insulin, and increased the subjective rating of satiety.

References for Item 11

A regulatory review and approval last Thursday of a potential blockbuster drug for diabetes is being viewed on Wall Street as a ”test case” that may reveal whether the Food and Drug Administration has become more cautious about safety.

Researchers report that the addition of a drug, spironolactone, to standard blood pressure-lowering therapy helps reduce both blood pressure and the amount of albumin protein in urine by 33%, a measure of kidney impairment.

The FDA has approved the investigational oral medicine for the treatment of type 2 diabetes, for use as monotherapy and in combination with metformin.